We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Regular Smear Tests Raises Chances of Cervical Cancer Cure

By LabMedica International staff writers
Posted on 22 Mar 2012
The detection of cervical cancer by screening can considerably increase a women's chance of surviving this malignant neoplasm, which in the early stages may be completely asymptomatic. More...


The rationale of cervical screening by the Papanicolaou test (Pap smear) is to reduce the incidence of cancer by the detection and treatment of precursors and a secondary aim is the early detection of invasive disease, which might improve the prognosis thereby also reducing mortality from the disease.

Scientists at the Uppsala University (Gävle, Sweden) and the Karolinska Institutet, (Stockholm, Sweden) examined all 1,230 women diagnosed with cervical cancer in Sweden between 1999 and 2001 in a prospective cohort study. The team examined screen-detected cancers, those with an abnormal smear result one to six months prior to cancer diagnosis, as well as symptomatic cancers, which were all the remaining cases.

At least seven years of potential follow-up were available from diagnosis of cervical cancer for all the women. Five years after diagnosis, 440 out of the 1,230 women had died. Among them, 373 had a recorded death due to cervical cancer. Thirty-one women died from other cancers, and 36 died of diagnoses not related to cancer. Results from the study revealed that there was a 92% cure rate for women who attended cervical screening, compared to 66% of women who were diagnosed by symptoms. This finding demonstrates a considerable increase in survival chances for those who attended cervical screening than women who did not. Furthermore, the researchers found that women who were overdue for an examination had lower chances of survival than women who attended screening following an invitation.

In addition, the team found that 75% of the 373 women who died from the disease did not undergo a cervical smear in the advised time frame. Half of the women who died from cervical cancer within five years of diagnosis were over the recommended age for screening. Women with interval cancers and an abnormal smear test result during the past six years had a nonsignificantly higher cure proportion than women with only a normal smear test result. If this difference is real, the reason might be that women with abnormal smear test results are followed up to a greater extent than women with normal smear test results.

The authors concluded that detection of invasive cancer by cervical screening implies a favorable prognosis compared with cancer being detected based on symptoms. The effect was stronger than what is reflected in downstaging and was not attributable to lead time bias. In addition, women with symptomatic interval cancers had a better prognosis than women with symptomatic cancers who did not have a smear test within the recommended screening interval. The effect on cervical cancer cure should be included when evaluating cervical screening programs. The study was published on March 1, 2012, in the British Medical Journal (BMJ).

Related Links:

Uppsala University
Karolinska Institutet



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Sample Transportation System
Tempus1800 Necto
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Microbiology

view channel
Image: The groundbreaking salmonella antimicrobial resistance prediction platform has demonstrated 95% accuracy (Photo courtesy of Yujie You et al., DOI: 10.1016/j.eng.2025.01.013)

New Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance

Antimicrobial-resistant Salmonella strains are a growing public health concern due to the overuse of antimicrobials and the rise of genetic mutations. Accurate prediction of resistance is crucial for effective... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.